ORIGINAL RESEARCH article
Front. Oncol.
Sec. Hematologic Malignancies
Longitudinal Analysis of Usage and Public Awareness of Tyrosine Kinase Inhibitors for CML
Provisionally accepted
Adrian E Schroer1,2,3
Tiffany Javadi4Ankit Mehta3Furkan Torlak3Joseph R. McFarland3Girish Kumar3Alex da Silva3
Jamaal Benjamin3Moaz M. Choudhary3Akram Sadeghi3
Philipp le Coutre5Michael J. Blaha2
Philipp Berning2,3
Omar Dzaye2,3*- 1Charité University Medicine Berlin, Berlin, Germany
- 2Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, United States
- 3Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, United States
- 4Emory University Department of Pathology and Laboratory Medicine, Atlanta, United States
- 5Charite - Universitatsmedizin Berlin Medizinische Klinik mit Schwerpunkt Hamatologie Onkologie und Tumorimmunologie CBF, Berlin, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The treatment landscape of chronic myeloid leukemia (CML) has evolved with the introduction of second-and third-generation tyrosine kinase inhibitors (TKIs), offering potential advantages over imatinib. We analyzed prescription trends and public awareness of TKIs to assess the adoption of newer agents. Monthly US prescription data from the IQVIA National Prescription Audit (NPA) and Google Trends search volumes from March 1, 2017, to November 31, 2024, were analyzed for visual and quantitative trends and correlation patterns. Studied TKIs included imatinib (first generation), dasatinib, bosutinib, nilotinib (second generation), and ponatinib, asciminib (third generation). Second-generation TKIs increased by 14.4% (15,171 to 17,363 average monthly prescriptions) between 2017 and 2024, while the use of imatinib declined (-10.0%, from 18,704 to 16,835). Bosutinib (+144.1%) and dasatinib (+27.8%) usage increased during this period, while nilotinib prescriptions decreased (-26.0%). Third-generation TKIs saw substantial growth (696 to 2,123 average monthly prescriptions), led by ponatinib (+86.6%) and asciminib (+235.0% since 2022). Online search volumes strongly correlated with prescription trends, particularly for newer TKIs: asciminib (r = 0.85), bosutinib (r = 0.74), nilotinib (r = 0.74), ponatinib (r = 0.63), and dasatinib (r = 0.51). Imatinib showed little correlation (r = 0.21). Prescription patterns varied across disciplines, with Advanced Practice Providers (APPs) prescribing imatinib 9% less frequently than internists/primary care physicians (PCPs). These data highlight a shift toward newer TKIs in CML treatment, mirroring guideline recommendations and rising public awareness. Online search trends complement traditional prescription monitoring, offering near real-time insights into evolving prescribing practices and drug adoption.
Keywords: tyrosine kinase inhibitor usage, CML treatment, public awareness, Infodemiology, Google Trends
Received: 23 Sep 2025; Accepted: 24 Oct 2025.
Copyright: © 2025 Schroer, Javadi, Mehta, Torlak, McFarland, Kumar, da Silva, Benjamin, Choudhary, Sadeghi, le Coutre, Blaha, Berning and Dzaye. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Omar Dzaye, omar.dzaye@utsouthwestern.edu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.